This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

High Tide Reports Second Quarter 2026 Financial Results Featuring Record Revenue of $179.3MM, and Adjusted EBITDA of $13.9MM

Newswire.ca - Mon Jun 15, 3:00PM CDT

The Company Also Reports Positive Free Cash Flow and Net Income

The Company's German Medical Cannabis Subsidiary, Remexian Pharma GmbH (Remexian) Generated Record Revenue of $31.6 Million with Gross Margins Increasing to 27%

Read more at newswire.ca

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).